keyword
https://read.qxmd.com/read/38408060/pilot-rct-comparing-low-dose-naltrexone-gabapentin-and-placebo-to-reduce-pain-among-people-with-hiv-with-alcohol-problems
#1
RANDOMIZED CONTROLLED TRIAL
Judith I Tsui, Sarah L Rossi, Debbie M Cheng, Sally Bendiks, Marina Vetrova, Elena Blokhina, Michael Winter, Natalia Gnatienko, Miroslav Backonja, Kendall Bryant, Evgeny Krupitsky, Jeffrey H Samet
BACKGROUND: To estimate the effects on pain of two medications (low-dose naltrexone and gabapentin) compared to placebo among people with HIV (PWH) with heavy alcohol use and chronic pain. METHODS: We conducted a pilot, randomized, double-blinded, 3-arm study of PWH with chronic pain and past-year heavy alcohol use in 2021. Participants were recruited in St. Petersburg, Russia, and randomized to receive daily low-dose naltrexone (4.5mg), gabapentin (up to 1800mg), or placebo...
2024: PloS One
https://read.qxmd.com/read/38393784/low-dose-naltrexone-a-possible-option-for-fibromyalgia
#2
JOURNAL ARTICLE
Manasa Irwin, Sarah Winter
No abstract text is available yet for this article.
February 2024: American Family Physician
https://read.qxmd.com/read/38352659/low-dose-naltrexone-and-nad-for-the-treatment-of-patients-with-persistent-fatigue-symptoms-after-covid-19
#3
JOURNAL ARTICLE
Anar Isman, Andy Nyquist, Bailey Strecker, Girish Harinath, Virginia Lee, Xingyu Zhang, Sajad Zalzala
A subset of patients experiences persistent fatigue symptoms after COVID-19, and patients may develop long COVID, which is characterized by lasting systemic symptoms. No treatments for this condition have been validated and are urgently warranted. In this pilot study, we assessed whether treatment with low-dose naltrexone (LDN, 4.5 mg/day) and supplementation with NAD + through iontophoresis patches could improve fatigue symptoms and quality of life in 36 patients with persistent moderate/severe fatigue after COVID-19...
March 2024: Brain, behavior, & immunity health
https://read.qxmd.com/read/38301136/efficacy-and-safety-of-low-dose-naltrexone-for-chronic-pain
#4
JOURNAL ARTICLE
Madison N Irwin, David A Cooke, Daniel Berland, Vincent D Marshall, Michael A Smith
Naltrexone is a mu-opioid receptor antagonist increasingly used as an analgesic for chronic pain at low doses. This retrospective, observational cohort study was conducted at an academic medical center to evaluate low-dose naltrexone (LDN) efficacy and describe its use in routine clinical practice. Adults receiving LDN, doses <10 mg for ≥1 month, seen at an outpatient pain clinic from January 1, 2014 to April 1, 2022 were included. The primary outcome was change in the Pain, Enjoyment of Life, and General Activity (PEG) score after LDN...
February 1, 2024: Journal of Pain & Palliative Care Pharmacotherapy
https://read.qxmd.com/read/38267326/low-dose-naltrexone-improves-post-covid-19-condition-symptoms
#5
JOURNAL ARTICLE
Leonardo Tamariz, Elizabeth Bast, Nancy Klimas, Ana Palacio
PURPOSE: Treatments for myalgic encephalomyelitis and chronic fatigue syndrome can be adapted for post-COVID-19 condition. Our aim was to compare treatments in patients from our post-COVID-19 clinic. METHODS: We conducted a retrospective cohort study and included consecutive patients enrolled in our post-COVID-19 clinic. We included patients who received low-dose naltrexone, amitriptyline, duloxetine, and physical therapy, and evaluated improvements in fatigue, pain, dyspnea, and brain fog recorded in the electronic health record...
January 23, 2024: Clinical Therapeutics
https://read.qxmd.com/read/38258679/is-low-dose-naltrexone-for-fibromyalgia-another-treatment-disappointment
#6
JOURNAL ARTICLE
Winfried Häuser, Mary-Ann Fitzcharles
No abstract text is available yet for this article.
January 2024: Lancet Rheumatology
https://read.qxmd.com/read/38258677/naltrexone-6-mg-once-daily-versus-placebo-in-women-with-fibromyalgia-a-randomised-double-blind-placebo-controlled-trial
#7
RANDOMIZED CONTROLLED TRIAL
Karin Due Bruun, Robin Christensen, Kirstine Amris, Henrik Bjarke Vaegter, Morten Rune Blichfeldt-Eckhardt, Lars Bye-Møller, Anders Holsgaard-Larsen, Palle Toft
BACKGROUND: Low-dose naltrexone is used to treat fibromyalgia despite minimal evidence for its efficacy. This trial aimed to investigate whether 12-week treatment with 6 mg low-dose naltrexone was superior to placebo for reducing pain in women with fibromyalgia. METHODS: We did a single-centre, randomised, double-blind, placebo-controlled trial in Denmark. We enrolled women aged 18-64 years who were diagnosed with fibromyalgia. Participants were randomly assigned 1:1 to receive low-dose naltrexone (6 mg) or an identical-appearing placebo, using a computerised algorithm with no stratifications applied...
January 2024: Lancet Rheumatology
https://read.qxmd.com/read/38213152/simultaneous-determination-of-levo-tetrahydropalmatine-and-naltrexone-in-rat-plasma-by-lc-ms-ms-and-its-application-in-a-pharmacokinetic-study
#8
JOURNAL ARTICLE
Kun Feng, Sherwin K B Sy, Mingming Yu, Zhihua Lv, Meixing Yan
BACKGROUND: Levo-tetrahydropalmatine and low-dose naltrexone are used in association with reducing cocaine-related cravings, but there are no analytical methods for the quantitative simultaneous analysis of this drug combination. OBJECTIVE: A highly selective and sensitive LC-MS/MS assay was developed and validated to simultaneously quantify l-THP and naltrexone. The analytical method for l-THP offers improved sensitivity compared to previously published methods...
January 10, 2024: Current Pharmaceutical Biotechnology
https://read.qxmd.com/read/38100664/case-study-personalized-oral-low-dose-naltrexone-titration-for-pain-management
#9
JOURNAL ARTICLE
Franklin Rodriguez, Maria Carvalho, Fabiana Banov
Naltrexone is a competitive opioid receptor antagonist indicated to treat opioid and alcohol dependence. In the U.S., naltrexone is commercially available as 50-mg tablets, and the adult dosage strength typically ranges between 50 mg once daily and 100 mg once daily. However, there is evidence to suggest that naltrexone prescribed in low doses, about 1/10th of the daily standard dosage, may be effective in managing a myriad of chronic conditions, including pain refractory to conventional pharmacological treatments...
2023: International Journal of Pharmaceutical Compounding
https://read.qxmd.com/read/38050177/alcohol-use-disorder-in-the-perioperative-period-a-summary-and-recommendations-for-anesthesiologists-and-pain-physicians
#10
JOURNAL ARTICLE
Olabisi Lane, Vats Ambai, Arjun Bakshi, Sudheer Potru
Excessive alcohol consumption and alcohol use disorder (AUD) increase the risk of perioperative morbidity and mortality. Aspiration, malnutrition, coagulopathies, seizures, and hemodynamic alterations are only a few of the major concerns related to acute alcohol intoxication and AUD. There are also numerous physiological effects, changes in medication metabolism and pharmacology, and adverse events related to chronic alcohol consumption. These are all important considerations for the anesthesiologist in the perioperative management of a patient with AUD...
November 30, 2023: Regional Anesthesia and Pain Medicine
https://read.qxmd.com/read/37863661/patients-perspective-quality-of-life-and-treatment-goals-in-hailey-hailey-disease-lessons-learned-from-the-german-national-registry
#11
JOURNAL ARTICLE
D Rogner, L Heimerl, S Heyer, T Biedermann, E Sattler, A Zink
BACKGROUND: Hailey-Hailey disease (HHD) remains a difficult-to-treat dermatosis and little is known about the patient's perception of the disease activity, the treatment success, and its impact on quality-of-life (QoL). OBJECTIVE: To obtain better understanding of HHD patients' needs regarding their medical condition, financial burden, QoL, subjective well-being and treatment thereof as well as satisfaction to evaluate common treatments' "real-life" relevance. METHODS: With initiation of the national registry for DD (Morbus Darier, MD) and Hailey-Hailey Disease (HH) MDHHgermany, patients with HHD diagnosis were included starting June 2020...
October 20, 2023: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/37846912/a-mixture-of-nalbuphine-azaperone-and-medetomidine-for-immobilizing-ringtails-bassariscus-astutus
#12
JOURNAL ARTICLE
Lindsay N Somers, DeWaine H Jackson, Katie M Dugger, Julia D Burco
We evaluated a combination of nalbuphine HCl (40 mg/mL), azaperone tartrate (10 mg/mL), and medetomidine HCl (10 mg/mL), a combination known as NAM or NalMed-A, in 23 ringtails (Bassariscus astutus) during 29 handling events for a radio-collaring study in southern Oregon, US, from August 2020 to March 2022. The combination was delivered to ringtails by hand injection at 0.075 mL NAM per estimated 1 kg body mass. The mean (± standard deviation, SD) dosage calculated post hoc was 3.366 (±0.724) mg/kg nalbuphine, 0...
October 1, 2023: Journal of Wildlife Diseases
https://read.qxmd.com/read/37817626/anesthesia-of-zoo-managed-african-painted-dogs-lycaon-pictus-using-a-dexmedetomidine-ketaminebutorphanol-midazolam-combination
#13
JOURNAL ARTICLE
Allison E Dianis, Richard R Sim, Ronan Eustace, Kimberly A Thompson
Zoo-managed adult African painted dogs ( Lycaon pictus ; n = 17) were anesthetized with mean dosages of dexmedetomidine 5 µg/kg, ketamine 1.93 mg/kg, butorphanol 0.2 mg/kg, and midazolam 0.15 mg/kg IM. Times to induction milestones (mean ± SD or median [range]) were initial effects at 2 min (1-4 min), recumbency at 3.2 ± 1.1 min, and intubation at 11.6 ± 1.3 min. Two dogs required isoflurane supplementation for intubation. Anesthesia was antagonized with mean dosages of atipamezole 0.05 mg/kg IM, naltrexone 0...
October 2023: Journal of Zoo and Wildlife Medicine: Official Publication of the American Association of Zoo Veterinarians
https://read.qxmd.com/read/37809234/is-fibromyalgia-a-fashionable-diagnosis-or-a-medical-mystery
#14
REVIEW
Giustino Varrassi, Martina Rekatsina, Serge Perrot, Elyse Bouajina, Antonella Paladini, Stefano Coaccioli, Marco Antonio Narvaez Tamayo, Piercarlo Sarzi Puttini
Despite its prevalence, there is no clear-cut diagnostic path or treatment paradigm for fibromyalgia; this can lead to a multiplicity of symptoms and comorbid conditions that complicate care. "Overlapping symptoms" describe conditions that can occur concomitantly with fibromyalgia and include migraine, irritable bowel syndrome, obesity, and pelvic pain syndromes. A variety of pharmacologic and nonpharmacologic treatments are available for fibromyalgia, but treatment is best personalized for an individual and recognizes potential comorbidities...
September 2023: Curēus
https://read.qxmd.com/read/37804660/low-dose-naltrexone-use-for-the-management-of-post-acute-sequelae-of-covid-19
#15
JOURNAL ARTICLE
Hector Bonilla, Lu Tian, Vincent C Marconi, Robert Shafer, Grace A McComsey, Mitchel Miglis, Philip Yang, Andres Bonilla, Lauren Eggert, Linda N Geng
The global prevalence of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) stands at approximately 43 % among individuals who have previously had acute COVID-19. In contrast, in the United States, the National Center for Health Statistics (NCHS) estimates that around 11 % of individuals who have been infected with SARS-CoV-2 go on to experience long COVID. The underlying causes of PASC remains under investigation, and there are no currently established FDA-approved therapies. One of the leading hypotheses for the cause of PASC is the persistent activation of innate immune cells with increase systemic inflammation...
November 2023: International Immunopharmacology
https://read.qxmd.com/read/37800846/efficacy-and-safety-of-three-different-opioid-based-immobilisation-combinations-in-blesbok-damaliscus-pygargus-phillipsi
#16
JOURNAL ARTICLE
A Roug, C Smith, J P Raath, L Cr Meyer, L L Laubscher
African wildlife species are increasingly being immobilised with combinations of a low dose of potent opioids combined with medetomidine and azaperone. The physiological effects of these combinations in comparison to conventional potent opioidazaperone combinations have scarcely been evaluated. In this cross-over study conducted on eight captive blesbok, we compared the physiological variables of blesbok immobilised with 2 mg of thiafentanil + 10 mg of azaperone (TA); 0.5 mg thiafentanil + 1.5 mg medetomidine (TM), and 0...
September 26, 2023: Journal of the South African Veterinary Association
https://read.qxmd.com/read/37752934/complex-presentations-identification-and-treatment-of-mast-cell-activation-syndrome-and-associated-conditions-a-case-report
#17
Alexandra M Quinn
Mast Cell Activation Syndrome (MCAS) is only a recently recognized, multisystem disorder that has been historically underrecognized due its estimated high prevalence. Recognition, testing, and treatment all pose unique challenges to condition management. The condition warrants more concern due to its prevalence and under recognition. Of equal importance in this case is the overlap seen between conditions such as MCAS, gastric dysmotility often manifesting as small intestine bacterial overgrowth (SIBO), dysautonomia, joint hypermobility disorders such as hypermobile Ehlers Danlos Syndrome (h-EDS) or other hypermobility spectrum disorders (HSD), and autoimmunity...
September 2023: Integrative Medicine
https://read.qxmd.com/read/37729143/is-low-dose-naltrexone-effective-in-chronic-pain-management
#18
RANDOMIZED CONTROLLED TRIAL
Roxanne Radi, Harriet Huang, Jason Rivera, Corey Lyon, Kristen DeSanto
YES. Low-dose naltrexone is as effective as amitriptyline in the treatment of painful diabetic neuropathy and has a superior safety profile (strength of recommendation [SOR], B; single randomized controlled trial [RCT]). Low-dose naltrexone significantly reduced pain by 32% in inflammatory conditions and 44% in neuropathic conditions (SOR, B; single retrospective cohort study). Doses as low as 5.4 mg were found to reduce pain in 95% of patients with fibromyalgia (SOR, B; single prospective dose-response study)...
September 2023: Journal of Family Practice
https://read.qxmd.com/read/37706146/low-dose-naltrexone-use-in-postural-orthostatic-tachycardia-syndrome-a-case-series
#19
JOURNAL ARTICLE
Samantha J Stallkamp Tidd, Christopher Cantrell, Brady D Greene, Robert Wilson
Introduction In recent years, low-dose naltrexone has emerged as a novel off-label therapy for many chronic conditions including postural orthostatic tachycardia syndrome (POTS), however, there is little evidence for its efficacy. Methods In this institutional review board (IRB)-approved case series, the charts of six tilt table-confirmed patients with POTS who underwent a trial of low-dose naltrexone (LDN) at our institution were reviewed. Medical history, subjective description of symptom severity, the continuation of therapy, tolerability, and scores on patient-reported outcome measures (Patient-Reported Outcomes Measurement Information System {PROMIS} Fatigue, PROMIS physical and mental health, Generalized Anxiety Disorder Assessment {GAD}-7, Patient Health Questionnaire {PHQ}-9, and Composite Autonomic Symptom Score {COMPASS}) were collected at therapy initiation and six to 12 months after the start of LDN...
August 2023: Curēus
https://read.qxmd.com/read/37641995/combination-therapy-a-new-tool-for-the-management-of-obesity
#20
JOURNAL ARTICLE
Pranav Kumar Prabhakar
Obesity is a long-term lifestyle problem that can lead to disastrous consequences. Lifestyle interventions are one of the initial lines of management strategies for obesity but in long term, it is not very effective in the management of obesity. Some people also manage their weight with bariatric surgery, which is now the most effective obesity treatment. Synthetic pharmaceuticals make a bridge between lifestyle modification and bariatric surgery-based obesity management. The major problem associated with monotherapy without side effects is that these are moderately effective and also need in higher doses...
August 25, 2023: Endocrine, Metabolic & Immune Disorders Drug Targets
keyword
keyword
118814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.